Patrys Limited (ASX: PAB)(Patrys,the Company), is pleased toannounce two key appointments in support of its upcoming Phase 1Aclinical trial, representing a significant milestone in the progression of the RLS-2202 program toward clinical-stage development: the engagement of CMAXas the clinical trial site and Alithia Life Sciences (Alithia)as the Contract Research Organisation (CRO)to oversee clinical trial management and operational execution. Together, these organisations will play complementary and distinct roles in the planning, execution, and management of the Company’s upcoming bridging PK, safety and tolerability studyin healthy volunteers.
